TVTX Travere Therapeutics, Inc.

NASDAQ
$56.85

Travere Therapeutics, Inc. (TVTX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bearish Selling ran elevated versus TVTX's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 9 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
8
40 transactions
Purchases
$0
0 shares
Sales
$66.3M
1,050,294 shares
Net activity
-$66.3M
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $66.3M 40 transactions · 1,050,294 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $6.6M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Dube Eric M 2 fills CHIEF EXECUTIVE OFFICER Sell 10b5-1 108,493 $64.61 $7.0M 439,688 −19.8% of holding
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER Sell 10b5-1 8,282 $65.07 $538.9K 117,066 −6.6% of holding
Dube Eric M 2 fills CHIEF EXECUTIVE OFFICER Sell 10b5-1 195,841 $63.45 $12.4M 529,011 −27% of holding
Heerma Peter 2 fills EVP, CHIEF COMMERCIAL OFFICER Sell 10b5-1 172,717 $63.43 $11.0M 196,179 −46.8% of holding
ROTE WILLIAM E. 2 fills Chief Research Officer Sell 10b5-1 112,850 $63.33 $7.1M 145,943 −43.6% of holding
Heerma Peter 4 fills EVP, CHIEF COMMERCIAL OFFICER Sell 10b5-1 102,190 $62.26 $6.4M 147,318 −41% of holding
ROTE WILLIAM E. 4 fills Chief Research Officer Sell 10b5-1 96,198 $62.25 $6.0M 130,488 −42.4% of holding
Dube Eric M 4 fills CHIEF EXECUTIVE OFFICER Sell 10b5-1 95,666 $62.26 $6.0M 465,054 −17.1% of holding
Cline Christopher R. 4 fills CHIEF FINANCIAL OFFICER Sell 10b5-1 50,508 $62.34 $3.1M 110,543 −31.4% of holding
Inrig Jula 4 fills EVP, Head of R&D & CMO Sell 10b5-1 44,674 $62.34 $2.8M 119,775 −27.2% of holding
REED ELIZABETH E 4 fills Chief Legal Officer and GC Sell 10b5-1 37,500 $62.34 $2.3M 120,963 −23.7% of holding
Calvin Sandra 3 fills SVP, CHIEF ACCOUNTING OFFICER Sell 10b5-1 5,375 $62.33 $335.0K 43,453 −11% of holding
Meckler Jeffrey A 4 fills Director Sell 10b5-1 20,000 $67.31 $1.3M 109,800 −15.4% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.